There was once an athlete who stepped onto the cycling stage.
Every time he opened his mouth, he would boast, “Just a few cycles of EPO will make your endurance explode and double your recovery speed.”
He pushed his hematocrit to 55%, deluding himself into thinking he was a living biochemical weapon.
The ending was predictable.
Instead of standing on the podium, he was struck down by pulmonary embolism, confined to a hospital bed, forced to watch the competition on TV.
This is the most miserable wreckage left behind by outdated tactics.
An act of suicide, obsessing over oxygen-carrying capacity to the point of turning blood into viscous sludge, ultimately transforming one’s own blood vessels into a minefield.
This is not a strategy.
It is merely a battlefield blunder orchestrated by the epitome of sheer ignorance.
The first to be cut down on the battlefield are the soldiers who fail to calculate the true risks of their weapons.
EPO’s hematopoietic action, Erythropoiesis, has always been a double-edged sword.
While it increases red blood cell count to enhance oxygen transport capacity, it simultaneously raises blood viscosity, placing an overload on the heart and creating blood clots.
There’s something even worse.
It also flips the switch for Angiogenesis, which becomes fuel for cancer cell growth.
If you want to grow tumors instead of muscle, just keep prescribing it that way.
But the real battlefield does not exist for such fools.
A true tactician does not blame the weapon.
They select and modify the weapon.
If you still believe relics like EPO are the main force on the battlefield, you are merely an amateur who hasn’t even grasped the essence of this game.
EPO is not just a simple erythrocyte stimulant; it is a cytokine that affects the entire system.
The goal is singular: to completely excise the dangerous hematopoietic function and cancer cell growth promotion effects, and extract only the tactical assets of neuroprotection and tissue regeneration.
The agents tasked with this mission are the non-hematopoietic EPO derivatives, the “Ghost Operators.”
Carbamylated EPO, or CEPO, is a stealth bomber.
While conventional EPO grabs two EPORs to send hematopoietic signals, CEPO twists its structure to infiltrate via a completely different pathway: the EPOR and common beta receptor (BCR) complex.
The result: it evades all enemy radar networks of hematopoiesis, angiogenesis, and blood pressure elevation, precisely striking only the target of tissue protection.
It eliminates the target without leaving widespread collateral damage.
This is a true precision weapon.
The peptide derivative, pHBSP or ARA 290, is a special infiltration unit.
It is an ultra-compact peptide comprising only a portion of the Helix-B structure of the EPO protein, allowing it to cross the blood-brain barrier and head straight to the brain due to its size.
They do not interfere with hematopoiesis.
Their mission is to suppress brain inflammation, repair damaged neurons, and block chronic pain signals.
For athletes suffering from central nervous system fatigue, peripheral neuropathy, and end-of-season brain fog, it is the most critical recovery asset.
Low-sialic-acid EPO, aka NeuroEPO, is a rapid deployment force.
It is designed with reduced sialic acid content at the end of its molecule, causing it to be rapidly broken down in the liver, leaving no chance to induce hematopoietic effects.
Administered intranasally, it reaches the brain directly within 5 minutes, performs its short-term mission of neuroprotection and cognitive function enhancement, and promptly exits the battlefield.
A short, powerful strike.
That is NeuroEPO.
The battlefield has now shifted from blood volume to a fight for the quality of the system.
There is a bodybuilder referred to as “N”.
An IFBB Pro who survived 15 years on the battlefield, bearing the medals of victory along with the aftereffects of neuralgia, joint inflammation, and end-of-season brain fog.
His outdated coaching system prescribed a low-dose EPO protocol from a bygone era: 500iu twice a week.
Initially, he felt a slight surge in vitality.
However, after 4 weeks, his blood pressure skyrocketed to 145/95, and his hematocrit levels surpassed 51%, triggering danger warnings.
The headaches felt during training signaled that his blood vessels were turning into time bombs.
This operation ended in failure, leaving only losses.
The tactics were immediately revised.
All EPO administration was halted, and a new protocol was issued.
The tactical objective was nervous system stabilization and systemic inflammation control.
The asset deployed was ARA 290.
The protocol was 4mg, subcutaneous injection every other day, for a total 8-week operation.
By the 2nd week, his blood pressure and hematocrit had perfectly normalized.
Not a single hematopoietic side effect was observed.
The real change began from the 4th week.
The chronic pain in his elbows and knees that had plagued him for years significantly decreased, and his sleep quality drastically improved with increased REM sleep.
Even in a state of extreme carbohydrate depletion at the end of the season, his concentration remained unbroken.
As the brain fog lifted, his posing and muscle control on stage became much more refined.
This was not simply a battle to increase red blood cells.
It was high-level engineering, repairing the damaged system from within and optimizing the neural signaling network.
He no longer used blood as his weapon.
He began to dominate the system itself.
But these tactics cannot be mimicked by just anyone.
Only commanders who can accurately read their own data and perfectly understand the characteristics of the assets are qualified to execute them.
First, analyze the battlefield.
Before initiating the operation, you must secure your current status through a blood test.
Check Hematocrit (HCT) and Hemoglobin (Hb) with a CBC, and assess systemic inflammation with hs-CRP.
Moving without this data is like stepping into a minefield blindfolded.
Second, the Nervous System Enhancement Protocol.
The goals are cognitive function enhancement, stress tolerance strengthening, and central nervous system recovery.
The asset is NeuroEPO.
One nasal spray per session, totaling 100-150 IU, 30 minutes before high-intensity training or in situations requiring extreme focus.
This is a hit-and-run tactic utilizing rapid absorption and a short half-life.
Especially when integrated into routines right before the stage, like pre-judging or pre-posing, it maximizes nervous system control and muscle-signal synchronicity.
Third, the System Recovery Protocol.
The goals are chronic inflammation suppression, neural and soft tissue damage repair, and maximizing recovery capacity.
The assets are ARA 290 or CEPO.
ARA 290 is administered at 4mg subcutaneously every other day, for a minimum of 8 weeks.
CEPO is deployed for long-term recovery strategies, positioned precisely according to individual conditions, leveraging its advantage of no hematopoietic side effects.
Particularly, when CEPO is used concurrently with ARA 290, a synergy occurs between inflammation suppression and neural regeneration, making it the optimal combination for recovery strategies during the off-season.
Reality is ruthless.
These assets are not things you can get prescribed like cold medicine at your local clinic.
They belong to the realm of cutting-edge research chemicals, with legal supply chains being extremely limited.
The real battlefield begins with the information war.
Victory is determined by whether you can secure the necessary weapons.
Amateurs obsess over muscle size and hematocrit levels.
They view the body as a mere pile of parts, believing that stuffing more from the outside will make them stronger.
But masters see the system.
Why contaminate the entire vascular system with outdated EPO that endangers the whole body?
If neural recovery is the goal, simply use ARA 290 to precision-strike that specific pathway.
True power comes not from brute firepower, but from precision and control that extract maximum efficiency from minimal resources.
Building the body is merely a means.
The true goal is to hack and dominate the entire system, including all variables: inflammation, recovery, neural signals, and hormonal feedback.
The chemical battlefield is already raging inside your blood vessels.
And the victors in this war are those who understand the system.
Key Papers on Non-Hematopoietic EPO Derivatives
1. Carbamylated EPO (CEPO) and Asialo EPO (AsialoEPO) Development
Paper Title: Derivatives of erythropoietin that are tissue protective but not erythropoietic – Science (2004)
A groundbreaking paper that first demonstrated the separation of EPO’s hematopoietic function from its tissue-protective function, introducing carbamylated EPO (CEPO).
Link: https://www.science.org/doi/10.1126/science.1095301
Paper Title: Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo – PNAS (2003)
The first study to demonstrate that AsialoEPO, created by removing sialic acid from EPO, exhibits broad neuroprotective effects without hematopoietic activity.
Link: https://www.pnas.org/doi/10.1073/pnas.1032233100
2. Peptide Derivatives (pHBSP/ARA 290, Epobis, etc.)
Paper Title: Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin – PNAS (2008)
Research showing that pHBSP (ARA 290), a small peptide derived from a specific structure (Helix B) of EPO, possesses tissue-protective effects without hematopoietic activity.
Link: https://www.pnas.org/doi/10.1073/pnas.0803450105
Paper Title: A new agonist of the erythropoietin receptor, Epobis, induces neurite outgrowth and promotes neuronal survival – Journal of Neurochemistry (2012)
A paper revealing that Epobis, a peptide derived from EPO’s AB loop, promotes neurite outgrowth and neuronal survival without hematopoietic activity.
Link: https://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2012.07722.x
3. Low-Sialic-Acid EPO (NeuroEPO)
Paper Title: An intranasal formulation of erythropoietin (Neuro-EPO) prevents memory deficits and amyloid toxicity in the APPSwe transgenic mouse model of Alzheimer’s disease – Journal of Alzheimer’s Disease (2017)
A study demonstrating that when NeuroEPO with low sialic acid content is administered intranasally, it prevents memory deficits and amyloid toxicity in an animal model of Alzheimer’s disease.
Link: https://content.iospress.com/articles/journal-of-alzheimers-disease/jad160875
